1,4-dihydro-2H-pyrido[1,2-a]indol-3-one | 1187081-15-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 1,4-dihydro-2H-pyrido[1,2-a]indol-3-one
• 英文别名: 2,4-dihydro-1H-pyrido[1,2-a]indol-3-one
• CAS: 1187081-15-7
• 化学式: C₁₂H₁₁NO
• 分子量: 185.225
• InChiKey: UQUHZLCVVOJPGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  21.5
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,4-dihydro-2H-pyrido[1,2-a]indol-3-one 在 sodium tetrahydroborate 、 水 、 氯化铵 作用下， 以 甲醇 为溶剂， 反应 0.5h， 生成 1,2,3,4-tetrahydro-pyrido[1,2-a]indol-3-ol
  参考文献：
  名称：

  [EN] TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
  [FR] COMPOSÉS TRICYCLIQUES EN TANT QU'ANTAGONISTES DES RÉCEPTEURS D2 DE LA PROSTAGLANDINE

  摘要：

  公开号：

  WO2010085820A3
• 作为产物：
  描述：

  在 sodium chloride 作用下， 以 水 、 二甲基亚砜 为溶剂， 生成 1,4-dihydro-2H-pyrido[1,2-a]indol-3-one
  参考文献：
  名称：

  Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis

  摘要：

  The synthesis of a series of tricyclic antagonists for the prostaglandin D(2) receptor DP2 (CRTH2) is disclosed. The activities of the compounds were evaluated in a human DP2 binding assay and a human whole blood eosinophil shape change assay. Potential metabolic liabilities of the compounds were addressed through in vitro CYP studies. The lead compound was demonstrated to have efficacy in a mouse model of allergic rhinitis following oral dosing. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.06.085

文献信息

• [EN] 7-(HETEROARYL-AMINO)-6,7,8,9-TETRAHYDROPYRIDO[1,2-A]INDOL ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS D'ACIDE 7-(HÉTÉROARYL-AMINO)-6,7,8,9-TÉTRAHYDROPYRIDO[1,2-A]INDOLACÉTIQUE ET LEUR UTILISATION EN TANT QUE MODULATEURS DU RÉCEPTEUR AUX PROSTAGLANDINES D2
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2012140612A1

  公开（公告）日：2012-10-18

  The present invention relates to 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives of the formula (I), wherein R1, R2, R3 and R4 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.

  本发明涉及公式（I）中的7-(杂环芳基氨基)-6,7,8,9-四氢吡啶并[1,2-a]吲哚乙酸衍生物，其中R1、R2、R3和R4如描述中所述，并且它们作为前列腺素受体调节剂，尤其作为前列腺素D2受体调节剂，在治疗各种前列腺素介导的疾病和紊乱中的用途，以及包含这些化合物的药物组合物和其制备方法。
• [EN] HETEROARYL COMPOUNDS FOR KINASE INHIBITION<br/>[FR] COMPOSÉS HÉTÉROARYLE D'INHIBITION DE LA KINASE
  申请人：ARIAD PHARMA INC

  公开号：WO2016183278A1

  公开（公告）日：2016-11-17

  Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFRand mutant HER2 activity, are described herein.

  本文描述了调节激酶活性的化合物和药物组合物，包括突变EGFR和突变HER2激酶活性，以及与激酶活性相关的疾病和病况的治疗方法、化合物和药物组合物，包括突变EGFR和突变HER2活性。
• Indole derivatives as crth2 receptor antagonists
  申请人：Wang Zhaoyin

  公开号：US20090286825A1

  公开（公告）日：2009-11-19

  Compounds according to formula (I) wherein the radicals R 1 , R 2 and R 3 are as herein defined, and wherein Ar represents an aryl group or heteroaryl group, preferably phenyl, n is 1 or 2, and the radical X represents a group selected from —C(R a )(R b )—, —C(R a )(R b )—C(R a )(R b )—, —C(R a )═C(R a )—, OC(R a )(R b )— or SC(R a )(R b )—. These compounds and their pharmaceutical acceptable salts are used in pharmaceutical compositions as prostaglandine D2 receptor antagonists useful in the treatment of CRTH2-mediated diseases such as respiratory, inflammatory or allergic conditions among others.

  化合物的公式为（I），其中基团R1、R2和R3如所定义，Ar代表芳基或杂芳基，优选苯基，n为1或2，基团X代表从—C（Ra）（Rb）—，—C（Ra）（Rb）—C（Ra）（Rb）—，—C（Ra）═C（Ra）—，OC（Ra）（Rb）—或SC（Ra）（Rb）—中选择的基团。这些化合物及其药学上可接受的盐用于制备药物组合物，作为前列腺素D2受体拮抗剂，对治疗CRTH2介导的疾病，如呼吸系统、炎症或过敏等病症有用。
• INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS
  申请人：Wang Zhaoyin

  公开号：US20110201641A1

  公开（公告）日：2011-08-18

  The compound (+) 7R-[[(4-fluorophenyl)sulfonyl] (methyl)ammo]-6,7,8,9-tetrahydropyrido[1,2-a]mdol-10-yl}acetic acid and pharmaceutically acceptable salts thereof are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-meidated diseases such as asthma.

  复合物（+）7R-[[(4-氟苯基)磺酰基]（甲基）氨基]-6,7,8,9-四氢吡啶[1,2-a]咪唑-10-基}乙酸及其药学上可接受的盐是PGD2受体，CRTH2的拮抗剂，因此在治疗和/或预防CRTH2介导的疾病，如哮喘中有用。
• TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
  申请人：Stearns Brian Andrew

  公开号：US20120004233A1

  公开（公告）日：2012-01-05

  Described herein are antagonists of PGD 2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists of PGD 2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD 2 -dependent or PGD 2 -mediated conditions or diseases.

  本文描述了PGD2受体拮抗剂。还描述了包括本文所述化合物的制药组合物和药物，以及使用这些PGD2受体拮抗剂的方法，单独或与其他化合物结合，用于治疗呼吸系统、心血管系统和其他PGD2依赖性或PGD2介导的疾病或病症。